Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma

Cancer Letters

Volumn 343, Issue 1, 2014, Pages 62-73

  Lee, Keun Woo ^a   Lee, Nam Kyung ^b,d   Ham, Seokjin ^c   Roh, Tae Young ^c   Kim, Seok Hyung ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Pohang University of Science and Technology (POSTECH)   (South Korea)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; EMT; Synovial sarcoma; Tumor initiating cells; Twist1

Indexed keywords

TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL POPULATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TRANSCRIPTION INITIATION SITE; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 84890858590     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.09.013     Document Type: Article

References (41)

1. Barco R., Garcia C.B., Eid J.E. The synovial sarcoma-associated SYT-SSX2 oncogene antagonizes the polycomb complex protein Bmi1. PloS One 2009, 4:e5060.
2. Thway K. Pathology of soft tissue sarcomas. Clinical Oncology 2009, 21:695-705.
3. Kawai A., Woodruff J., Healey J.H., Brennan M.F., Antonescu C.R., Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. The New England Journal of Medicine 1998, 338:153-160.
4. Saito T., Nagai M., Ladanyi M. SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. Cancer Research 2006, 66:6919-6927.
5. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: mirage or reality?. Nature Medicine 2009, 15:1010-1012.
6. Matushansky I., Hernando E., Socci N.D., Mills J.E., Matos T.A., Edgar M.A., Singer S., Maki R.G., Cordon-Cardo C. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. The Journal of Clinical Investigation 2007, 117:3248-3257.
7. Naka N., Takenaka S., Araki N., Miwa T., Hashimoto N., Yoshioka K., Joyama S., Hamada K., Tsukamoto Y., Tomita Y., Ueda T., Yoshikawa H., Itoh K. Synovial sarcoma is a stem cell malignancy. Stem Cells 2010, 28:1119-1131.
8. Riggi N., Suva M.L., De Vito C., Provero P., Stehle J.C., Baumer K., Cironi L., Janiszewska M., Petricevic T., Suva D., Tercier S., Joseph J.M., Guillou L., Stamenkovic I. EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells. Genes and Development 2010, 24:916-932.
9. Tirino V., Desiderio V., Paino F., De Rosa A., Papaccio F., La Noce M., Laino L., De Francesco F., Papaccio G. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2013, 27:13-24.
10. Terry J., Nielsen T. Expression of CD133 in synovial sarcoma. Applied Immunohistochemistry and Molecular Morphology: AIMM/Official Publication of the Society for Applied Immunohistochemistry 2010, 18:159-165.
11. Lohberger B., Rinner B., Stuendl N., Absenger M., Liegl-Atzwanger B., Walzer S.M., Windhager R., Leithner A. Aldehyde dehydrogenase 1, a potential marker for cancer stem cells in human sarcoma. PloS One 2012, 7:e43664.
12. Wu C., Wei Q., Utomo V., Nadesan P., Whetstone H., Kandel R., Wunder J.S., Alman B.A. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. Cancer Research 2007, 67:8216-8222.
13. Li L., Cserjesi P., Olson E.N. Dermo-1: a novel twist-related bHLH protein expressed in the developing dermis. Developmental Biology 1995, 172:280-292.
14. Martin A., Cano A. Tumorigenesis: Twist1 links EMT to self-renewal. Nature Cell Biology 2010, 12:924-925.
15. Phinney D.G. Twist, epithelial-to-mesenchymal transition, and stem cells. Stem Cells 2011, 29:3-4.
16. Lee K.W., Kim J.H., Han S., Sung C.O., Do I.G., Ko Y.H., Um S.H., Kim S.H. Twist1 is an independent prognostic factor of esophageal squamous cell carcinoma and associated with its epithelial-mesenchymal transition. Annals of Surgical Oncology 2012, 19:326-335.
17. Puisieux A., Valsesia-Wittmann S., Ansieau S. A twist for survival and cancer progression. British Journal of Cancer 2006, 94:13-17.
18. Tran P.T., Shroff E.H., Burns T.F., Thiyagarajan S., Das S.T., Zabuawala T., Chen J., Cho Y.J., Luong R., Tamayo P., Salih T., Aziz K., Adam S.J., Vicent S., Nielsen C.H., Withofs N., Sweet-Cordero A., Gambhir S.S., Rudin C.M., Felsher D.W. Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. PLoS Genetics 2012, 8:e1002650.
19. Mohseny A.B., Hogendoorn P.C. Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells 2011, 29:397-403.
20. Polyak K., Weinberg R.A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews. Cancer 2009, 9:265-273.
21. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117:927-939.
22. Lee K.W., Lee N.K., Kim J.H., Kang M.S., Yoo H.Y., Kim H.H., Um S.H., Kim S.H. Twist1 causes the transcriptional repression of claudin-4 with prognostic significance in esophageal cancer. Biochemical and Biophysical Research Communications 2012, 423:454-460.
23. Yang M.H., Hsu D.S., Wang H.W., Wang H.J., Lan H.Y., Yang W.H., Huang C.H., Kao S.Y., Tzeng C.H., Tai S.K., Chang S.Y., Lee O.K., Wu K.J. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nature Cell Biology 2010, 12:982-992.
24. Waterfall J.J., Meltzer P.S. Targeting epigenetic misregulation in synovial sarcoma. Cancer Cell 2012, 21:323-324.
25. Sung C.O., Lee K.W., Han S., Kim S.H. Twist1 is up-regulated in gastric cancer-associated fibroblasts with poor clinical outcomes. The American Journal of Pathology 2011, 179:1827-1838.
26. Pretto D., Barco R., Rivera J., Neel N., Gustavson M.D., Eid J.E. The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 2006, 25:3661-3669.
27. Piccinin S., Tonin E., Sessa S., Demontis S., Rossi S., Pecciarini L., Zanatta L., Pivetta F., Grizzo A., Sonego M., Rosano C., Dei Tos A.P., Doglioni C., Maestro R. A "twist box" code of p53 inactivation: twist box: p53 interaction promotes p53 degradation. Cancer Cell 2012, 22:404-415.
28. Maestro R., Dei Tos A.P., Hamamori Y., Krasnokutsky S., Sartorelli V., Kedes L., Doglioni C., Beach D.H., Hannon G.J. Twist is a potential oncogene that inhibits apoptosis. Genes and Development 1999, 13:2207-2217.
29. Miller S.J., Rangwala F., Williams J., Ackerman P., Kong S., Jegga A.G., Kaiser S., Aronow B.J., Frahm S., Kluwe L., Mautner V., Upadhyaya M., Muir D., Wallace M., Hagen J., Quelle D.E., Watson M.A., Perry A., Gutmann D.H., Ratner N. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Research 2006, 66:2584-2591.
30. Entz-Werle N., Stoetzel C., Berard-Marec P., Kalifa C., Brugiere L., Pacquement H., Schmitt C., Tabone M.D., Gentet J.C., Quillet R., Oudet P., Lutz P., Babin-Boilletot A., Gaub M.P., Perrin-Schmitt F. Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas, International journal of cancer. Journal International du Cancer 2005, 117:349-355.
31. Ocana O.H., Corcoles R., Fabra A., Moreno-Bueno G., Acloque H., Vega S., Barrallo-Gimeno A., Cano A., Nieto M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22:709-724.
32. Tsai J.H., Donaher J.L., Murphy D.A., Chau S., Yang J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22:725-736.
33. Yu W., Zhang Y., Ruest L.B., Svoboda K.K. Analysis of Snail1 function and regulation by Twist1 in palatal fusion. Frontiers in Physiology 2013, 4:12.
34. Bialek P., Kern B., Yang X., Schrock M., Sosic D., Hong N., Wu H., Yu K., Ornitz D.M., Olson E.N., Justice M.J., Karsenty G. A twist code determines the onset of osteoblast differentiation. Developmental Cell 2004, 6:423-435.
35. Eckert M.A., Lwin T.M., Chang A.T., Kim J., Danis E., Ohno-Machado L., Yang J. Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011, 19:372-386.
36. Russell K.C., Phinney D.G., Lacey M.R., Barrilleaux B.L., Meyertholen K.E., O'Connor K.C. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010, 28:788-798.
37. Davis S.R., Meltzer P.S. Modeling synovial sarcoma: timing is everything. Cancer Cell 2007, 11:305-307.
38. Haldar M., Hancock J.D., Coffin C.M., Lessnick S.L., Capecchi M.R. A conditional mouse model of synovial sarcoma: insights into a myogenic origin. Cancer Cell 2007, 11:375-388.
39. Haldar M., Randall R.L., Capecchi M.R. Synovial sarcoma: from genetics to genetic-based animal modeling. Clinical Orthopaedics and Related Research 2008, 466:2156-2167.
40. Takenaka S., Naka N., Araki N., Hashimoto N., Ueda T., Yoshioka K., Yoshikawa H., Itoh K. Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo. International Journal of Oncology 2010, 36:823-831.
41. Kadoch C., Crabtree G.R. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013, 153:71-85.